Articles related to RESEARCH & CLINICAL TRIALS

Subcutaneous administration of amivantamab demonstrated noninferiority to IV delivery while potentially offering enhanced patient convenience and reduced healthcare system burden.

Post-trial analysis reveals a 13% relative reduction in cardiovascular death and kidney disease progression risk, though this benefit primarily manifests in the first 12 months after treatment discontinuation.

In this randomized trial of 1,010 patients with stable DES undergoing noncardiac surgery, perioperative aspirin continuation showed no significant reduction in major adverse cardiac events compared to complete antiplatelet cessation.

Phase 2a clinical trials demonstrate benfotiamine’s ability to enhance synaptic activity while maintaining an excellent safety profile, even at doses exceeding normal thiamine blood levels.

The discovery of I-NCMs’ ability to simultaneously patrol blood vessels and infiltrate tumor environments opens new possibilities for treating therapy-resistant cancers.

Durvalumab consolidation therapy demonstrated unprecedented survival benefit in limited-stage SCLC, extending median overall survival by nearly two years compared to placebo.